Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma

C

Catholic University, Italy

Status

Completed

Conditions

Asthma

Treatments

Drug: Formoterol

Study type

Observational

Funder types

Other

Identifiers

NCT01786616
UCSC-AG-16

Details and patient eligibility

About

Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to salmeterol in asthmatics. Data concerning formoterol are more controversial in literature. The aim of this study was to verify whether homozygote for arginine-16 (ArgArg16) and homozygote for glycine-16 (GlyGly16) genotypes differently influence the long-term responsiveness to formoterol.

Enrollment

30 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Mild to moderate asthma
  • Stable clinical conditions

Exclusion criteria

  • Smokers
  • Current therapy with oral steroids
  • Exacerbations within the past 3 months

Trial design

30 participants in 1 patient group

Formoterol
Description:
12 mcg BID for four weeks
Treatment:
Drug: Formoterol

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems